The short answer
Blüher and colleagues compared survodutide against placebo and an open-label semaglutide arm in adults with type 2 diabetes, published in Diabetologia in 2024. The semaglutide arm was open-label and the trial was dose-finding, which makes this weaker evidence than a blinded head-to-head.
Key facts
- Compound
- Survodutide (BI 456906)
- Class
- GLP-1 / glucagon dual agonist
- Comparators
- Placebo and open-label semaglutide
- Population
- Adults with type 2 diabetes
- Published
- Diabetologia 2024 (PMID 38095657)
- Correction issued
- Diabetologia 2024 (PMID 38349400)
- Design
- Dose-response, not a pivotal head-to-head
What the trial was for
Dose-response. Its primary purpose was establishing how HbA1c and body weight reduction varied across survodutide doses, a dose-finding exercise. The semaglutide arm was included as a reference point, not as the trial's reason for existing.
Why open-label matters
Participants and investigators knew who was receiving semaglutide. Blinding exists because knowledge of assignment influences reported outcomes, adherence and adverse event reporting. An open-label comparator arm is informative context; it is not the same evidential object as a double-blind randomised comparison, and results from it should carry that qualification.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The confusion in circulation
Figures from this trial are routinely mixed with figures from a separate 46-week trial in participants with overweight or obesity without diabetes. Those are different populations, different durations and different endpoints. A number quoted without its population and duration attached cannot be checked, and in this compound's coverage that happens constantly.
Why a correction was published
Diabetologia issued a correction to the paper in 2024. Corrections are routine and usually minor, but they are part of the published record and citing the original without checking whether one exists is how errors persist. This site's citation checking now surfaces them.
What the glucagon component contributes
Survodutide adds glucagon receptor agonism to GLP-1 activity, which raises energy expenditure and mobilises hepatic fat. It is the same rationale behind retatrutide's third receptor, and it is why compounds in this class are also studied in metabolic liver disease rather than weight alone.
What it is not
Survodutide is investigational. Semaglutide is a licensed medicine. Neither is related to research material, and comparing their trial results has no bearing on anything supplied here.
Frequently asked questions
Why do quoted survodutide numbers vary so much?
Figures from this type 2 diabetes trial are frequently mixed with those from a separate 46-week trial in a different population without diabetes.
What does the glucagon receptor add?
Increased energy expenditure and mobilisation of hepatic fat, the same rationale as retatrutide's third receptor.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBlüher M et al., Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide. Diabetologia 2024 (PMID 38095657)pubmed.ncbi.nlm.nih.gov
- PubMedCorrection to Blüher M et al. Diabetologia 2024 (PMID 38349400)pubmed.ncbi.nlm.nih.gov
- PubMedCoskun T et al., LY3437943 triple agonist. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Failing to Show Non-Inferiority Is Not Showing InferiorityREDEFINE 4 missed its non-inferiority endpoint. That is a specific statistical statement, and it is not the same as the drug being worse.
- Satiety and Nausea Run Through Different CircuitsA 2024 Nature paper showed hindbrain GLP-1 receptor circuits for satiety and aversion are dissociable. Nausea may not be the price of appetite suppression.
- Three Head-to-Heads, One Common ComparatorSURMOUNT-5, REDEFINE 4 and TRIUMPH-5 all use tirzepatide. What it means when one compound becomes the field's reference point.
- What Open-Label Does to a Weight-Loss TrialREDEFINE 4's registry record lists masking as none. Why an unblinded weight trial is weaker evidence, and where the effect creeps in.
- Two Answers to the Same QuestionCagriSema pairs GLP-1 with amylin; tirzepatide pairs it with GIP. REDEFINE 4 was effectively the first direct test between those strategies.